PROTHENA CORP PLC ORDIN (PRTA) Covered Calls

PROTHENA CORP PLC ORDIN covered calls Prothena Corporation PLC researches and develops potential therapeutic monoclonal antibodies directed specifically to disease causing proteins. The therapies have a broad range of indications including Parkinson's disease and related synucleinopathies.

You can sell covered calls on PROTHENA CORP PLC ORDIN to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PRTA (prices last updated Fri 4:16 PM ET):

PROTHENA CORP PLC ORDIN (PRTA) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
14.51 -0.13 13.21 14.99 258K - 0.6B
Covered Calls For PROTHENA CORP PLC ORDIN (PRTA)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Sep 21 15 0.50 14.49 3.5% 35.5%
Dec 21 15 1.25 13.74 9.1% 26.2%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Prothena Corp. Plc is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion. It also focuses on therapeutic monoclonal antibodies directed specifically to disease causing proteins. The company's antibody-based product candidates target a number of potential indications including AL and AA forms of amyloidosis, Parkinson's disease and other related synucleinopathies and novel cell adhesion targets involved in inflammatory diseases and cancers. Prothena was founded on December 20, 2012 and is headquartered in Dublin, Ireland.